Leerink Partnrs Weighs in on MOLN FY2024 Earnings

Molecular Partners AG (NASDAQ:MOLN) – Research analysts at Leerink Partnrs issued their FY2024 earnings per share estimates for Molecular Partners in a note issued to investors on Thursday, March 6th. Leerink Partnrs analyst J. Chang expects that the company will earn ($1.93) per share for the year. The consensus estimate for Molecular Partners’ current full-year earnings is ($1.93) per share. Leerink Partnrs also issued estimates for Molecular Partners’ Q4 2024 earnings at ($0.45) EPS and FY2025 earnings at ($1.71) EPS.

Molecular Partners Trading Down 11.7 %

Shares of MOLN opened at $4.43 on Monday. The firm’s 50-day moving average is $5.09 and its two-hundred day moving average is $5.35. Molecular Partners has a twelve month low of $3.32 and a twelve month high of $12.70. The firm has a market capitalization of $178.61 million, a P/E ratio of -2.06 and a beta of 1.06.

Molecular Partners (NASDAQ:MOLN) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.11. Molecular Partners had a negative net margin of 1,043.01% and a negative return on equity of 39.31%.

Institutional Investors Weigh In On Molecular Partners

An institutional investor recently raised its position in Molecular Partners stock. BVF Inc. IL boosted its position in shares of Molecular Partners AG (NASDAQ:MOLN) by 205.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,353,968 shares of the company’s stock after purchasing an additional 910,747 shares during the quarter. BVF Inc. IL owned approximately 3.35% of Molecular Partners worth $6,458,000 at the end of the most recent reporting period. 26.55% of the stock is currently owned by institutional investors and hedge funds.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.